Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2- breast cancer in the US.

M Gouldson¹, Q Le², S Millen³, J Racz², B Arrick², D Hartzfeld², B Heald², S Eymere¹, J-P De La O², V Berdunov⁴, G Cuyun Carter²

¹Putnam, London, UK.

²Exact Sciences, Madison, Wisconsin, USA.

³Exact Sciences, London, UK.

⁴ThermoFisher Scientific, London, UK.

PubMed DOI

Abstract

BACKGROUND: In the US, breast cancer is the most common female cancer. Personalized treatment strategies, informed by genomic assays and germline genetic testing (GGT), can optimize therapeutic decisions and improve patient outcomes along the hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer treatment pathway. PURPOSE: To evaluate the cost-ef…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.